Physician profile
Heather Wetch
NPI 1922581271
$885.83
in general payments reported to CMS, 2019-2025
13 companies · $861 in 2025
The $861 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.27 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780 · Education: $80.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $780.40 |
| Education | $80.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $237.26 | 2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $222.19 | 2021-2025 | Ebglyss, Taltz |
| Genzyme Corporation | $157.19 | 2025 | |
| Abbvie INC. | $55.69 | 2025 | |
| Arcutis Biotherapeutics, INC. | $48.95 | 2025 | Zoryve |
| Leo Pharma INC. | $32.64 | 2025 | Anzupgo |
| Galderma Laboratories, L.P. | $30.31 | 2025 | Aklief |
| Novartis Pharmaceuticals Corporation | $24.86 | 2025 | |
| Incyte Corporation | $22.88 | 2025 | Opzelura |
| Ucb, INC. | $16.00 | 2025 | Bimzelx |
| Cranial Technologies, INC | $14.16 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Organon LLC | $10.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Wetch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.